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Antibody-mediated rejection is a significant contributor to organ transplant failure. The 
Bumgardner Lab has recently discovered a novel subset of CD8+ T cells (CD8+ TAb-supp cells) that 
express CXCR5 and suppress transplant-specific antibody (alloantibody), which results in 
prolonged transplant survival in mouse models. To further understand these cells, we set out to 
investigate the requirements for CXCR5+CD8+ TAb-supp cell development. Previous reports suggest 
that IFN- cytokine may be critical for the development of CD8+ TAb-supp cells, and I further 
hypothesized that CD4+ T cells are also important for their development. To investigate these 
hypotheses, wild-type mice or mice lacking IFN-, IFN- receptor (IFN-R), and/or CD4+ T cells 
were stimulated with allogeneic antigen. In some cohorts, naïve CD8+ T cells were adoptively 
transferred (AT) into stimulated mice. One week following stimulation, cells were isolated from 
the spleens of stimulated mice and analyzed for the CD8+ TAb-supp phenotype (CXCR5), activation 
(CD44), proliferation, and cytotoxic effector molecules. To date, we have found that the expression 
of CXCR5 on CD8+ T cells (wild-type, 13.5%) was downregulated in mice that lacked CD4+ T 
cells (6.8%; 2-fold) or IFN- (8.5%; 1.5-fold). While activation was not affected by IFN-γ or CD4+ 
T cells, proliferation of wild-type CXCR5+CD8+ T cells is dependent on host expression of IFN-γ 
(wild-type=33.5% versus IFN- KO=19.7%). In addition, the cytotoxic effector phenotype of 
activated CXCR5+CD8+ T cells is nearly abrogated when hosts are IFN-γ deficient (Lamp1: 
WT=70.0% versus IFN-γ KO=6.7%; FasL: WT=36.5% versus IFN-γ KO=6.7%). 
To date, experiments using mutant CD8+ T cells adoptively transferred into wild-type hosts 
show no variance in CXCR5 expression, activation, or effector molecule expression. Thus, our 
current data, despite relatively small sample sizes, suggests a critical role for both host IFN- 
expression and CD4+ T cells in maximizing CXCR5 expression on CD8+ T cells as well as 
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proliferation and the expression of cytotoxic effector molecules on CXCR5+CD8+ T cells. Our 
current hypothesis is that IFN-+CD4+ T cells are critically important for the development of 
CXCR5+CD8+ TAb-supp cells, and ongoing studies will continue to investigate the influence these 
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Organ transplantation is an efficacious therapeutic strategy for people suffering from organ 
damage or end-stage organ failure (1). The replacement of damaged tissue with healthy donor 
tissue has prolonged survival and improved the quality of life for these patients, but rejection, 
namely antibody-mediated rejection (AMR), of the transplanted tissue by the recipient’s immune 
system continues to be an obstacle in the long-term success of transplantation (2-4). The immune 
system is stimulated by foreign proteins from the transplanted tissue, namely major 
histocompatibility complex molecules, or MHC, and the immune-mediated responses can occur 
through cellular-mediated rejection or AMR (5). To date, cellular immune responses are largely 
inhibited by immunosuppressive therapy.  However, despite improvements, recipients can still 
produce antibodies that target the transplant (also known as “alloantibodies”) (6). Antibody-
mediated rejection occurs when a recipient’s B cells secrete alloantibodies that recruit cytotoxic 
complexes (complement) and other immune cells expressing cytotoxic molecules to kill allogeneic 
cells, compromising the transplanted organ (7). This mechanism is a major contributor to graft 
rejection, and therefore a deeper understanding of the AMR pathway is necessary to develop new 
and effective immunosuppressive therapies. 
The focus of our research is to gain a clearer understanding of the immune mechanisms 
contributing to alloantibody production and AMR, and to find highly specific interactions that can 
interrupt AMR without compromising protective immunity. Current therapies for AMR prevention 
consist of immunosuppressive drugs that weaken all immune system mechanisms, which can leave 
patients vulnerable to additional infections and cardiovascular risks (8, 9). An alternative to this 
approach is finding therapies that specifically target and suppress AMR-related immune responses, 




T cells have a significant increase in alloantibody compared to wild-type recipients, which 
indicated that CD8+ T cells play a critical role in the suppression of alloantibody (11). We further 
found that CD8+ T cells activated against transplanted cells (alloprimed) used cytotoxic 
mechanisms to kill alloantibody producing B cells, which led to decreased alloantibody (12). 
Subsequent experiments led to the discovery of a novel subset of CD8+ T cells that express 
CXCR5+, which is a receptor required for the recruitment of cells to the germinal centers of 
lymphoid tissue. In the germinal center (GC), GC B cells are major contributors to the production 
of antibody (13). Our lab has recently found that CXCR5+CD8+ T cells are critical to the reduction 
of alloantibody (14) and specifically kill antibody-producing GC B cells (unpublished 
observations). Our lab refers to this cell subset as antibody-suppressor CD8+ T cells (CD8+ TAb-
supp cells). The role of these cells may be clinically relevant as CXCR5+CD8+ T cells are also 
detectable in the peripheral blood of human kidney transplant recipients, and the quantity of these 
cells was shown to be inversely associated with the incidence of alloantibody production (15). 
Additionally, it has been previously reported that in the absence of CD8+ T cells, antibody 
production is enhanced in a variety of models including viral infection (16), bacterial infection 
(17), allergy (18, 19), transplant (20-23), and platelet transfusion (24), which suggests that the role 
of antibody-suppressive CD8+ T cells has a wide impact on immune responses. Thus, further 
investigation of these cells is warranted in both mouse models and human patients. 
One area that requires further investigation is how CXCR5+CD8+ T cells develop following 
antigen stimulation. We have previously reported that CD8+ T cells from an interferon-gamma 
(IFN-)-deficient host did not inhibit alloantibody in hepatocyte or kidney transplanted mice (11). 
We also considered the potential involvement of CD4+ T cells in the developmental process since 




CD4+ T cells for optimal activity (25), but it is currently unknown whether the development of 
CD8+ TAb-supp cells requires CD4+ T cell-mediated help. Based on this knowledge, we hypothesized 
that CD4+ T cells and IFN-γ are both critical for the development, activation, proliferation, and 
effector function of CD8+ TAb-supp cells. To address these developmental questions, we utilized 
mice from different strains, including wild-type (normal) and mice lacking IFN- (IFN-knock 
out, KO), the receptor to IFN- (IFN-R KO) or CD4+ T cells (CD4 KO or CD4-depletion). 
Following allogeneic protein stimulation, mice were tracked for the development of CXCR5+CD8+ 







C57BL/6 (wild-type; WT), CD4 knockout (KO), IFN-γ KO, IFN-γR KO, Jα18 KO, GFP 
transgenic (Tg), OT-I Tg x GFP Tg, mOVA Tg (all H-2b, Jackson, Bar Harbor, ME), and FVB/N 
(H-2q, Taconic, Hudson, NY) mouse strains were used in these studies. FVB/N and mOVA mice 
were the source of lysate used to stimulate the immune response in other mouse strains. Mice that 
were used as experimental hosts or as a source of donor cells were at least 6 weeks old, and all 
experiments were performed in accordance with the Institutional Animal Care and Use Committee 
of the Ohio State University (Protocol 201900000124). 
 
T cell isolation for adoptive transfer 
Splenocytes were isolated from mice, and CD8+ or CD4+ T cells were isolated from the bulk 
splenocytes with a negative selection column per manufacturer instructions (STEMCELL 
Technologies, Cambridge, MA; purity routinely >95%). A cohort of CD8+ T cells were stained 
with CellTrace Violet (Thermo Fisher, Walther, MA) at a dose half of the manufacturer’s 
recommendation (2.5 μM, mean fluorescent intensity (MFI) > 100-fold versus unstained). 
 
In vitro cytotoxicity assay 
Splenic CD8+ T cells were co-cultured with CFSE-stained target B cells at a 10:1 ratio for 4 hours 
at 37°C / 5% CO2. Propidium iodide (PI) was added to the cultures to measure cell death, and PI 
uptake by CFSE+ B cells was analyzed with flow cytometry. A LIVE/DEAD cell-mediated 






Livers were isolated from FVB/N (H-2q) and mOVA (H-2b) mice and placed in PBS (1 liver/4 mL 
PBS). The livers were diced and freeze/thawed for five cycles (-80°C freezing; room temperature 
thaw). The final solution was spun down to remove debris from the supernatant. Protein 
concentration was analyzed by the Bradford Coomassie brilliant blue assay and quantitated by 
spectrometry (Thermo Scientific Multiskan GO). 
 
Allogeneic stimulation of host mice and adoptive transfer 
Recipient mice were primed with allogeneic, FVB/N liver lysate or syngeneic, mOVA liver lysate 
through intraperitoneal injection (2 mg) on day 0. Several cohorts of mice were adoptively 
transferred with naïve CD8+ T cells stained with CellTrace Violet or naïve CD4+ T cells through 
a tail vein injection alongside the lysate stimulation. Additional cohorts of mice were depleted of 
CD4+ T cells with anti-CD4 monoclonal antibody (GK1.5; Bioexpress Cell Culture Services, West 
Lebanon, New Hampshire) through intraperitoneal injection (250 μg, day -3, -1).  
 
Flow cytometric analysis of lymphocytes and intracellular molecule staining 
Splenocytes were isolated from the recipient mice (day 7 post-FVB/N or mOVA lysate treatment) 
and underwent a four-hour incubation (37°C, 5% CO2) with Leukocyte Activation Cocktail (2 
μL/mL; PMA, ionomycin, and Brefeldin A; Becton Dickinson) or monesin (Thermo Fisher). 
Splenocytes were then stained for CD8 (Clone #53-6.7) and extracellular markers for chemokine 
receptors (CXCR5, clones #FAB6198G, 2G8, MU5UBEE, and L138D7), activation (CD44, clone 
#IM7; CD62L, clone #MEL-14), and effector molecules (Lamp1, clone #1D4B; FasL, clone 




and intracellular staining was performed for IFN-γ (clone #XMG1.2), Perforin (clone 
#eBio0MAK-D), and Granzyme B (clone #NGZB). Splenocytes were formalin-fixed after 
intracellular staining and analyzed with an LSR Fortessa flow cytometer. The cells were gated on 
lymphocytes, single-cell, and CD8+ T cells.  Additional analysis gated on CXCR5 and/or CD44 
before analyzing additional markers. 
 
Statistical analysis 
The distribution of data is represented by average ± standard error. A student t-test was used as a 







CXCR5 expression and activation peaks at day 7 post-transplant on CD8+ T cells. Our lab 
has previously performed time course studies on the expression of CXCR5 and CD44 on CD8+ T 
cells in hepatocyte transplant models to determine the optimal time of the development and 
activation of CXCR5+CD8+ T cells. A cohort of wild-type mice were transplanted with FVB/N 
hepatocytes and splenocytes were isolated from the mice at days 0, 2, 5, 7, 10, and 14 for flow 
cytometric analysis. The number of cells expressing CXCR5 on CD8+ T cells on day 7 (11.1±
1.1%; Figure 1A) was 8-fold greater than the number of CXCR5+CD8+ T cells on day 0 (1.4±
0.1%; p=0.0005). Similarly, the expression of CD44 on day 7 (30.4±1.8%; Figure 1B) was 
significantly elevated compared to CD44 expression on day 0 (3.0±0.5%; p=0.0001).  Since day 
7 post-transplant had maximal development and activation of CXCR5+CD8+ T cells, I utilized 
this time point for the investigation of developmental requirements of the CD8+ TAb-supp cell 
subset. In addition, we have previously reported that CD8+ TAb-supp cells are highly functional 
(inhibit alloantibody and kill antibody-producing B cells) on day 7 post-lysate treatment (14).  
 
CXCR5 expression on CD8+ T cells is dependent on CD4+ T cells, IFN-γ, and IFN-γR in the 
host. To analyze the role of CD4+ T cells and IFN-γ on CD8+ TAb-supp cell development, our early 
studies focused on how these components affected host CD8+ T cells. Cohorts of C57BL/6, CD4 
KO, IFN-γ KO, and IFN-γR KO mice were stimulated with allogeneic FVB/N liver lysate. An 
additional cohort of C57BL/6, IFN-γ KO, and IFN-γR KO were treated with anti-CD4 mAb, and 
the splenocytes from all cohorts were isolated on day 7 post-lysate treatment for flow cytometric 




significantly higher than the quantity of CXCR5+CD8+ T cells in IFN-γ KO mice (3.3±0.8%; 
p=0.021) or in IFN-γR KO mice (3.7±0.6%; p=0.024). A similar reduction in the quantity of 
CXCR5+CD8+ T cells was observed in CD4-depleted wild-type mice compared to wild-type mice 
(6.1±1.1%; p=0.167; Figure 2B) as well as in CD4 KO mice (2.0±0.3%; p=0.033). Interestingly, 
CXCR5+CD8+ T cells in IFN-γ KO mice (3.3±0.8%; Figure 2C) were elevated compared to 
CXCR5+CD8+ T cells in IFN-γ KO mice that were CD4-depleted (4.9±0.4%; p=0.152), but this 
change in expression was not observed between IFN-γR KO mice (3.7±0.6%) versus CD4-
depleted, IFN-γR KO mice (3.1±0.3%; p=0.294). These significant reductions in CXCR5+CD8+ T 
cells in each of the genetically modified hosts indicated that host CD4+ T cells, IFN-γ, and IFN-
γR all have a potential role in the development of functional CD8+ TAb-supp cells.  
 
Maximal quantity of CXCR5+CD8+ T cells is dependent on host expression of IFN-γ and the 
presence of CD4+ T cells. In order to investigate the role of CD4+ T cells, IFN-γ, and IFN-γR on 
CXCR5+CD8+ T cell development, we employed two separate strategies for analyzing the impact 
of genetically modified hosts and donor cells. The first strategy adoptively transferred naïve wild-
type CD8+ T cells into genetically modified hosts, and the second strategy adoptively transferred 
genetically modified CD8+ T cells into wild-type hosts. To better understand the role of host IFN-
γ and CD4+ T cells on CXCR5 expression, C57BL/6, CD4-depleted C57BL/6, IFN-γ KO, and 
CD4-depleted IFN-γ KO mice were adoptively transferred with naïve OT-I x GFP CD8+ T cells 
and treated with mOVA liver lysate. Splenocytes were isolated from the host mice on day 7 post-
lysate treatment and stained for CXCR5 and CD8 expression. When naïve wild-type CD8+ T cells 
were adoptively transferred into wild-type hosts, the quantity of CXCR5+CD8+ T cells 




(6.8±0.0%; p=0.020) and hosts lacking IFN-γ cytokine (8.5±0.6%; p=0.020). The number of 
CXCR5+CD8+ T cells was further inhibited in IFN-γ KO mice when CD4+ cells were depleted 
(5.0±0.4%; p=0.011) compared to wild-type mice. The roles of host IFN-γ and IFN-γR on CXCR5 
expression were further analyzed by adoptive transfer of naïve GFP+CD8+ T cells into C57BL/6, 
IFN-γ KO, and IFN-γR KO mice alongside FVB/N lysate stimulation. The quantity of adoptively 
transferred wild-type CD8+ T cells that expressed CXCR5 in the lysate stimulated wild-type hosts 
(9.0±0.4%; Figure 3B) was two-folds greater than the quantity of adoptively transferred 
CXCR5+CD8+ T cells in IFN-γR KO hosts (5.0±0.9%; p=0.017), but the quantity of adoptively 
transferred CXCR5+CD8+ T cells in IFN-γ KO hosts remained unchanged compared to the wild-
type hosts (7.1±1.7%; p=0.214). After determining that IFN-γ, IFN-γR, and CD4+ T cells impacted 
CXCR5 expression on CD8+ T cells, we next analyzed how these components influenced the 
activation of the CXCR5+CD8+ T cells.  
 
Proportion of CXCR5+CD8+ T cells that are activated does not depend on host IFN-γ or 
CD4+ T cells. After host CD4+ T cells and IFN-γ cytokine were shown to influence the quantity 
of CXCR5+CD8+ T cells, further studies were performed to determine the role these components 
had on the activation of the CXCR5+CD8+ T cell subset. Cohorts of C57BL/6, CD4-depleted 
C57BL/6, IFN-γ KO, and CD4-depleted IFN-γ KO mice were stimulated with mOVA lysate and 
adoptively transferred with OT-I x GFP CD8+ T cells. Splenocytes isolated from the host mice on 
day 7 underwent flow cytometric analysis for CD44, CXCR5, GFP, and CD8 expression. The 
activation of adoptively transferred CXCR5+CD8+ T cells in the wild-type cohort (45.2±3.2%, 
Figure 4A) was unchanged when compared to the activation of the same cell subset in the IFN-γ 




as shown in CD4-depleted wild-type mice (44.5±4.6%; p=0.451) and in CD4-depleted, IFN-γ KO 
mice (38.8±0.2%; n=3; p=0.111) compared to the activation of a wild-type host. To further analyze 
the role of IFN-γ in the host, C57BL/6, IFN-γ KO, and IFN-γR KO mice were stimulated with 
FVB/N lysate and adoptively transferred with GFP+ wild-type CD8+ T cells. Flow cytometric 
analysis on day 7 showed that the activation of GFP+CXCR5+CD8+ T cells in wild-type mice (27.5
±2.1%, Figure 4B) did not differ from the activation in IFN-γ KO (29.8±2.1%; p=0.289) or IFN-
γR KO (30.0±3.6%; p=0.389) mice. Three cohorts of GFP+ C57BL/6 mice were adoptively 
transferred with wild-type, IFN-γ KO, or IFN-γR KO CD8+ T cells to further analyze the role of 
IFN-γ on the adoptive transfer cells. The activation of adoptively transferred, CXCR5+CD8+ T 
cells in wild-type hosts (21.9±1.8%, Figure 4C) was slightly lower than the activation of IFN-γ 
KO CD8+ T cells in the wild-type hosts (28.7±1.2%; p=0.031), but the activation of adoptively 
transferred IFN-γR KO CXCR5+CD8+ T cells showed no difference from the wild-type control 
(30.6±10.8%; p=0.276). Since the quantity of CXCR5+CD8+ T cells is altered in the absence of 
CD4+ T cells or IFN-γ while activation is not, we next investigated if CD4+ T cells and IFN-γ 
impact the proliferative ability of this cell subset. 
 
Proliferation of developing, activated CXCR5+CD8+ T cells is dependent on host IFN-. 
Cohorts of C57BL/6, CD4-depleted C57BL/6, IFN-γ KO, and CD4-depleted IFN-γ KO mice were 
adoptively transferred with CellTrace Violet-stained CD8+ T cells isolated from OT-I x GFP mice 
and treated with mOVA liver lysate to analyze the role of CD4+ T cells and IFN-γ on the 
proliferation of activated CD8+ T cells. Splenocytes from the host mice were isolated on day 7 




activated (CD44+) CXCR5+CD8+ T cells was significantly higher than CXCR5-CD8+ T cells in 
C57BL/6, CD4-depleted C57BL/6, and CD4-depleted IFN-γ KO mice (p<0.03; Figure 5A), 
suggesting that CXCR5+CD8+ T cells may have a heightened proliferative capacity following 
antigen stimulation compared to CD8+ T cells that do not express CXCR5. The proliferation of 
adoptively transferred activated CXCR5+CD8+ T cells in the wild-type hosts (33.5±1.5%) was also 
significantly higher than the proliferation of activated CXCR5+CD8+ T cells in the IFN-γ KO hosts 
(19.7±1.2%, p=0.011). 
 
Cytotoxic effector phenotype of activated CXCR5+CD8+ T cells is critically dependent on 
host IFN-γ. After determining the impact of IFN-γ on CXCR5 expression and activation, we next 
analyzed how this cytokine affected the expression of cytotoxic effector molecules on CD8+ T 
cells. Cohorts of wild-type, IFN-γ KO, and IFN-γR KO mice were treated with FVB/N lysate and 
adoptively transferred with naïve wild-type GFP+CD8+ T cells. On day 7 post-lysate stimulation, 
the splenocytes from the host mice were isolated and analyzed by flow cytometry. The expression 
of FasL on adoptively transferred, activated CXCR5+CD8+ T cells in wild-type mice (36.5±5.6%; 
Figure 6A) was significantly higher than the number of cells expressing FasL on the same cell 
subset in IFN-γ KO hosts (6.7±5.4%; p=0.010). Additionally, the number of activated 
Lamp1+CXCR5+CD8+ T cells in the wild-type host mice (70.0±6.2%; Figure 6A) was 10-fold 
greater than the number of activated, Lamp1+CXCR5+CD8+ T cells in IFN-γ KO mice (6.7±5.4%, 
p=0.002). To determine if IFN-γ was also important on the adoptive transfer cells, several cohorts 
of GFP+ wild-type mice were adoptively transferred with naïve wild-type, IFN-γ KO, and IFN-γR 
KO CD8+ T cells. The host mice were treated with FVB/N liver lysate, and splenocytes were 




cells that expressed FasL (50.0±35.4%, Figure 6B) was greater than the percent of activated IFN-
γ KO CXCR5+CD8+ T cells expressing FasL (8.3±6.8%, p=0.181). However, the percent of wild-
type CXCR5+CD8+ T cells expressing Lamp1 (62.5±26.5%, Figure 6B) did not show a significant 
difference from the percent of IFN-γ KO CXCR5+CD8+ T cells expressing Lamp1 (48.3±21.1%, 
p=0.383). 
 
CD8+ T cells rely on host IFN-γ and CD4+ T cells to effectively kill alloprimed B cells. 
Our lab has previously performed an in vitro cytotoxicity assay to determine whether IFN-γ or 
CD4+ T cells impact the development of cytotoxic effector function of CD8+ T cells towards 
antibody-producing (IgG+) B cells. Wild-type, IFN-γ KO, and CD4 KO mice were transplanted 
with FVB/N hepatocytes, and splenic CD8+ T cells were isolated from these mice on day 7 post-
transplant for a cytotoxicity co-culture. The CD8+ T cells from different strains were co-cultured 
with naïve wild-type or primed wild-type IgG+ B cells (day 7 posttransplant; CD8 KO recipient) 
at a 10:1 ratio. After a 4-hour incubation, the propidium iodide uptake was measured for each 
culture to determine the cytotoxicity of the CD8+ T cells against the B cells. The percent 
cytotoxicity in the wild-type CD8+ T cell and IgG1+ B cell co-culture (6.5±0.7%; Figure 7) was 
13-fold greater than the cytotoxicity of IFN-γ KO CD8+ T cells (0.5±0.1%; p<0.001) and CD4 KO 
CD8+ T cells (0.5±0.6%; p<0.001) against IgG1+ B cells. This indicates that both IFN-γ and CD4+ 
T cells are critical for the development of specific effector function against alloprimed B cells. 
Cytotoxicity against the naïve B cells was unchanged between the different CD8+ T cell groups 
compared to the wild-type CD8+ T cells (WT CD8+: 1.5±0.7%; IFN-γ KO CD8+: 2.5±0.7%; 
p=0.095, CD4 KO CD8+: 2.0±0.1%, p=0.161). The CD8+ T cells also showed no cytotoxicity 





CXCR5 expression on CD8+ T cells is dependent on IFN-γ+CD4+ T cells and IFN-γR+CD4+ 
T cells in the host mouse. The critical role of CD4+ T cells in CD8+ TAb-supp cell development was 
further supported by the quantity of CXCR5+CD8+ T cells in CD4 KO mice treated with FVB/N 
lysate. In the absence of CD4+ T cells, CXCR5+CD8+ T cell development was low (2.9±0.5%). A 
cohort of CD4 KO mice received C57BL/6, IFN-γ KO, or IFN-γR KO CD4+ T cells through 
adoptive transfer. Splenocytes isolated on day 7 showed an increase in the number of 
CXCR5+CD8+ T cells in CD4 KO mice that were reconstituted with wild-type CD4+ T cells 
(5.2±1.1%, Figure 8) compared to CD4 KO mice without adoptive transfer (2.9±0.5%; p=0.156). 
However, CD4 KO mice that were adoptively transferred with IFN-γ KO CD4+ T cells showed a 
slightly reduced quantity of CXCR5+CD8+ T cells (3.2±0.9%; p=0.212) compared to the mice 
adoptively transferred with wild-type CD4+ T cells. Similarly, CD4 KO mice reconstituted with 
IFN-γR CD4+ T cells showed a minimal difference in the quantity of CXCR5+CD8+ T cells 
compared to mice lacking CD4+ T cells (2.3% versus 3.2±0.9% in control), which implies that 
IFN-γ and/or IFN-γR on CD4+ T cells may play a critical role in the ability of CD8+ T cells to 
express CXCR5. The impact of IFN-γ+ and IFN-γR+ CD4+ T cells on the phenotype of the CD8+ 
TAb-supp is a promising preliminary result in further understanding the mechanism of development 
for this subset, and future studies will continue to analyze the role these cells have on the 






The Bumgardner Lab is the first group to report that a subset of CD8+ T cells are antibody-
suppressing T cells that inhibit alloantibody production (12, 14, 26), kill B cells (12, 14), and 
enhance allograft survival (14, 26). Since these studies were the first to analyze the function 
antibody-suppressing CXCR5+CD8+ T cells, the developmental process for these cells was still 
unknown. Our current study found that both host IFN-γ and CD4+ T cells elevated the quantity of 
CXCR5+CD8+ T cells on day 7 after lysate treatment. While activation of the CXCR5+CD8+ T 
cells was unaffected by either IFN- or CD4+ T cells, the proliferation of CXCR5+CD8+ T cells 
significantly increased when IFN-γ was present in the host. Host IFN-γ also elevated the 
expression of FasL and Lamp1 on CD8+ T cells, which may be the cause of the abrogated 
cytotoxicity for CD8+ T cells against IgG+ B cells in IFN-γ KO mice. Pilot data also suggests that 
IFN-γ+ and IFN-γR+ CD4+ T cells significantly increase the quantity of CXCR5+CD8+ T cells but 
do not cause a change in the activation of the CD8+ TAb-supp cell subset. 
Since we show that both host IFN-γ and CD4+ T cells maximize the quantity of 
CXCR5+CD8+ T cells, there is a potential role for Th1 CD4+ T cell help in the expression of 
CXCR5 on CD8+ T cells. Th1 CD4+ T cells secrete IFN-γ cytokine (27), so the decrease in 
CXCR5+CD8+ T cells in IFN-γ KO mice may be caused by a skewed Th2 profile. It is also possible 
that other IFN-γ secreting cells, such as macrophages (28) or iNKT cells (29), impact the 
expression of CXCR5 on CD8+ T cells as well. However, since CXCR5 expression was not 
completely abrogated in the IFN-γ KO mice, it is likely that other mechanisms contribute to the 
CXCR5 expression beyond IFN-γ signaling and additional pathways for expression will be 
investigated in future studies. In contrast, our studies also indicated that both IFN-γ and CD4+ T 




mechanisms contribute to the activation of the CD8+ TAb-supp cells. Further investigation is required 
to determine the role of CD4+ T cells (and the precise CD4+ T cell subset) in enhancing the quantity 
of CXCR5+CD8+ T cells as well as the role of iNKT cells on the activation of CD8+ TAb-supp cells 
since iNTK cells are reported to enhance CD8+ T cells effector function following antigen 
stimulation (30-33). We will also consider the role of other antigen-presenting cells, such as 
dendritic cells and macrophages, on CXCR5 expression and the activation of the CXCR5+CD8+ T 
cell subset. 
Additionally, our group observed that the proliferation of the CXCR5+CD8+ T cells was 
upregulated when IFN-γ was present in the host. Interestingly, we also found that activated 
CXCR5+CD8+ T cells proliferated at a higher rate than CXCR5-CD8+ T cells. This enhanced 
proliferation of the CXCR5-expressing subset is akin to PD-1+ICOS+CXCR5+CD8+ T cells that 
are highly proliferative, anti-viral cells with stem-cell-like characteristics (34, 35). While these 
anti-viral cells have no impact on antibody production, their proliferation results in CD8+ T cells 
that lose CXCR5 expression. In our studies, proliferating alloprimed CXCR5+CD8+ T cells 
maintain CXCR5 expression and have been reported to be phenotypically distinct from anti-viral 
CD8+ T cells through the lack of expression PD-1 and ICOS (14). We have also found that our 
CXCR5+CD8+ T cell subset is a short-lived effector cell (CD44+KLRG1+IL-2Rb+IL-7R-; data not 
shown), whereas the PD-1+ICOS+CXCR5+CD8+ T cells have gene signatures that indicate a 
memory precursor phenotype (KLRG1+IL-2Rb-IL-7R+) (34). In contrast to the proliferation of 
alloprimed CXCR5+CD8+ T cells, alloprimed CXCR5-CD8+ T cells did not proliferate following 
lysate stimulation. Previous studies tracking the proliferation of antigen-specific rejector CD8+ T 
cells showed that approximately 95% of alloprimed CD8+ T cells proliferate following transplant 




CD4+ T cells. We have also recently indicated that CXCR3+CXCR5-CD8+ T cell subsets (CD8+ 
Trej cells) (14) are cytotoxic to allogeneic cells and require “direct” antigen presentation with allo-
MHC (from viable transplants) (37). Since rejector cells are CXCR5-negative, it is likely that the 
low proliferation of CXCR5-CD8+ T cells cannot effectively respond to allogeneic lysate 
(“indirect” antigen presentation). Despite these differences, the increased proliferative capacity of 
the CD8+ TAb-supp cells is a new characteristic that our group had not previously observed for this 
subset. While activated CXCR5+CD8+ T cells in host mice with IFN-γ had a higher proliferative 
capacity, further investigation is required to determine the role of IFN-γR on CD8+ T cells for 
proliferation. 
Finally, the expression of cytotoxic effector molecules was also upregulated by host IFN-
γ. FasL and Lamp1 expression were significantly reduced on wild-type CD8+ T cells that were 
adoptively transferred into mice without IFN-γ, but granzyme B and perforin remained unchanged 
on the wild-type CD8+ T cells adoptively transferred into mice deficient in either IFN-γ or IFN-
γR. Since Lamp1 indicates perforin release (38), the drop in Lamp1 suggests that without IFN-γ 
in the host, CXCR5+CD8+ T cells lack the ability to release perforin as a means for the cytotoxic 
killing of IgG+ B cells. The downregulated release of perforin (indicated by reduced Lamp1 
expression) in the absence of IFN-γ may cause the decrease in cytotoxic effector function for CD8+ 
T cells from IFN-γ KO hosts. This possibility will be investigated in future in vitro or in vivo 
cytotoxicity assays that utilize CXCR5+CD8+ T cells rather than bulk CD8+ T cells. Additionally, 
the reduction in FasL expression when IFN-γ is absent suggests that IFN-γ is critical to maintaining 
the FasL/Fas interactions. Both perforin and FasL have been shown as a key cytotoxic pathways 
for downregulating alloantibody in transplant recipients (12). This hypothesis is further 




without IFN-γ. The expression of both perforin and granzyme B further differentiates 
CXCR5+CD8+ T cells from the antibody-enhancing CXCR5+CD8+ T cells that express PD-1 but 
lack granzyme B and perforin (39-41). Pilot studies also indicated that IFN-γ+ and IFN-γR+ CD4+ 
T cells were critical for both CXCR5 expression and cytotoxic effector molecule expression on 
CXCR5+CD8+ T cells, but further data is needed to confirm these findings. 
While these initial findings show that both CD4+ T cells and IFN-γ impact the development 
of CD8+ TAb-supp cells, the relatively small sample size for each experiment requires repeat studies 
before the conclusions can be fully supported. Additionally, since IFN-γ KO mice are skewed 
towards Th2 CD4+ T cell (42), it is possible that the CD8+ T cells did not fully mature or develop 
in these host mice and skewed the observed results. Future studies will also analyze the role of 
CD4+ T regulatory cells and IL-4 KO CD4+ T cells on the development of CD8+ TAb-supp cells by 
adoptively transferring wild-type CD4+ T cells, IFN-γ KO CD4+ T cells, IL-4 KO CD4+ T cells, 
or flow-sorted CD4+ Treg cells (CD3+CD25+FoxP3+) (43) to determine their impact on the various 
development parameters. IL-4 KO mice are skewed towards a Th1 profile, so if Th1 CD4+ T cells 
are required for CD8+ TAb-supp cell development, these mice would have expression patterns that 
contrast the observations in IFN-γ KO hosts. In addition to IFN-γ and CD4+ T cells, we are also 
interested in the role that the microenvironment plays in CD8+ TAb-supp cell development. Current 
studies indicate that fully matured, alloprimed CD8+ TAb-supp cells traffic to the lymph node and 
spleen, but it is unclear if this location is required for development. We hypothesize that lymph 
nodes may be a key site for these cells to develop into the functional subset we have previously 
observed, and we will begin investigating this hypothesis with mice that lack functional lymph 
nodes (Ltα KO mice) and/or spleens (splenectomized mice). Beyond the microenvironment, it is 




precursors, or if primed CXCR5-CD8+ T cells have the potential to develop a CXCR5+ phenotype. 
If future studies find that the CXCR5-negative cells can develop CXCR5, then we will also 
investigate the cytokines and cellular interactions that promote this change to optimize the number 
of available CXCR5+CD8+ TAb-supp cells. 
The data presented in these studies provide a foundation to maximize CD8+ TAb-supp cells 
both in vivo and in vitro for clinical applications. We have previously shown that human kidney 
transplant recipients that develop donor-specific antibody (DSA) have significantly lower numbers 
of peripheral CXCR5+CD8+ T cells when compared to recipients that do not make DSA (44), 
which indicates a potential role for these cells in human DSA reduction. With further investigation 
into the developmental mechanisms, we can investigate strategies to optimize CD8+ TAb-supp in 
human patients receiving organ transplants. These strategies may involve therapies that can expand 
the CD8+ TAb-supp cell population in a test tube for future transfer into the recipient, or therapies 
that can expand the CD8+ TAb-supp cell population within the human transplant recipient to prolong 



















Figure 1: CXCR5 and CD44 expression on CD8+ T cells peaks at day 7  
C57BL/6 (wild-type, H-2b) mice were transplanted with hepatocytes isolated from FVB/N (H-2q) mice. Splenocytes 
were isolated from the transplanted mice on days 0, 2, 5, 7, 10, and 14 post-transplant and analyzed by flow cytometry. 
A) The quantity of wild-type CXCR5+CD8+ T cells on day 7 (11.1±1.1%; n=3; p=0.0005 vs. day 0) was the highest 
of any of the time points. B) CD44 expression also peaked at day 7 (30.4±1.8%; n=3; p=0.0001 vs. day 0) compared 
to the other time points measured. C) A representative flow cytometry plot for CXCR5 and CD44 expression was 
created to demonstrate how the cell markers were quantified. The lymphocyte population was selected with the 
forward and side scatter profiles of the cells. Lymphocytes were then gated on single cells to remove any cells that 
were conjoined when passing through the laser. Single cells were gated for CD8+ expression by using an FMO (flow-
minus-one) control that lacked the CD8+ antibody. The location of the gate for CXCR5 expression on CD8+ T cells 












Figure 2: CD4+ T cells, IFN-γ, and IFN-γR enhance CXCR5 expression of host CD8+ T cells. 
C57BL/6 (wild-type), CD4 KO, IFN-γ KO, and IFN-γR KO mice (all H-2b) were stimulated with FVB/N liver lysate 
(H-2q). An additional group of C57BL/6, IFN-γ KO, and IFN-γR KO mice were treated with anti-CD4 mAb on days 
-3 and -1 before lysate stimulation. Splenocytes were isolated from the cohorts of mice on day 7 and analyzed by flow 
cytometry. A) The number of CXCR5+ wild-type CD8+ T cells (10.0±2.5%; n=4) was 3-folds greater than IFN-γ KO 
CD8+ T cells (3.3±0.8%; n=5; p=0.021) and IFN-γR KO CD8+ T cells (3.7±0.6%; n=5; p=0.024). B) The quantity of 
CXCR5+CD8+ T cells in wild-type mice (10.0±2.5%; n=4) was also higher than the number of CXCR5+CD8+ T cells 
in CD4-depleted wild-type mice (6.1±1.1%; n=3; p=0.167) or CD4 KO mice (2.0±0.3%; n=3; p=0.033). C) The 
percent of CXCR5+CD8+ T cells in IFN-γ KO mice (3.3±0.8%; n=5) was lower than the percent of CXCR5+CD8+ T 
cells in CD4-depleted IFN-γ KO mice (4.9±0.4%; n=3; p=0.152). No significant difference was observed in 
CXCR5+CD8+ T cell quantity between IFN-γR KO mice (3.7±0.6%; n=5) and CD4-depleted IFN-γR KO mice 











Figure 3: IFN-γ and wild-type CD4+ T cells enhance the development of CXCR5+CD8+ T cells.  
A) C57BL/6 (wild-type) and IFN-γ KO mice (both H-2b) were treated with mOVA (H-2b) liver lysate, and CD8+ T 
cells from OT-I x GFP mice were adoptively transferred (AT) into the lysate-treated hosts. Cohorts of each strain were 
treated with anti-CD4 mAb to deplete CD4+ T cells. On day 7 post-lysate treatment, splenocytes were purified from 
the host mice. Flow cytometric analysis of AT CD8+ T cells expressing CXCR5 in the C57BL/6 hosts (13.5±1.2%; 
n=3) was significantly elevated compared to CD4-depleted C57BL/6 hosts (6.8±0.0%; n=3; p=0.020) and IFN-γ KO 
hosts (8.5±0.6%; n=3; p=0.020). The quantity of AT CXCR5+CD8+ T cells in IFN-γ KO hosts was further suppressed 
following CD4 depletion (5.0±0.4%; n=3; p=0.011) compared to the wild-type host. B) C57BL/6, IFN-γ KO, and 
IFN-γR KO (H-2 b) mice were treated with FVB/N (H-2q) liver lysate (2mg protein) and adoptively transferred with 
naïve GFP+ WT CD8+ T cells. Flow cytometric analysis of splenocytes isolated on day 7 showed that the quantity of 
CXCR5+CD8+ T cells was (9.0±0.4%; n=3) in C57BL/6 hosts. The proportion of CXCR5+CD8+ T cells was 
unchanged on AT CD8+ T cells in IFN-γ KO hosts (7.1±1.7%; n=3; p=0.214) compared to the wild-type, but the 











    
  
  
Figure 4: The proportion of activated CD8+ Tab-supp cells is not affected by host CD4+ T cells or IFN-γ. 
A) C57BL/6 (wild-type) and IFN-γ KO mice (both H-2b) were treated with mOVA (H-2b) liver lysate (2 mg protein). 
CD8+ T cells from OT-I x GFP mice were adoptively transferred (AT) into the mice treated with mOVA lysate, and 
cohorts of C57BL/6 and IFN-γ KO mice were treated with anti-CD4 mAb. Splenocytes were isolated from the host 
mice on day 7 post-lysate treatment, and flow cytometric analysis of CD44+ on the adoptive transfer CXCR5+CD8+ T 
cells in C57BL/6 mice (45.2±3.2%; n=3) was unchanged compared to CXCR5+CD8+ T cells expressing CD44 in 
CD4-depleted C57BL/6 mice (44.5±4.6%; n=3; p=0.451). The proportion of adoptive transfer CXCR5+CD8+ T cells 
in IFN-γ KO expressing CD44 was also unchanged compared to the wild-type control (45.7±4.8%; n=3; p=0.465), 
and the proportion of CD44+CXCR5+CD8+ T cells was slightly reduced in the CD4-depleted, IFN-γ KO mice 
(38.8±0.2%; n=3; p=0.111). B) C57BL/6, IFN-γ KO, and IFN-γR KO mice (H-2b) were adoptively transferred with 
naïve GFP+ WT CD8+ T cells and treated with FVB/N liver lysate (H-2q; 2 mg protein). Flow cytometric analysis on 
day 7 showed that CD44 expression on GFP+CD8+ T cells in wild-type mice (27.5±2.1%) was not significantly 
different than the proportion of CD44 expression on AT CD8+ T cells in IFN-γ KO mice (29.8±2.1%; n=3; p=0.289) 
or IFN-γR KO mice (30.0±3.6%; n=3; p=0.389). C) Cohorts of GFP+ C57BL/6 mice were adoptively transferred with 
CD8+ T cells isolated from C57BL/6, IFN-γ KO, and IFN-γR KO mice (H-2b) and lysate treated with FVB/N liver 
lysate (H-2q; 2 mg protein). Splenocytes were isolated from the hosts on day 7, and flow cytometric analysis of CD44+ 
on GFP- CXCR5+CD8+ T cells was performed. The wild-type control (21.9±1.8%; n=3) showed no significant 
difference from the cohort with IFN-γR KO CD8+ T cells (30.6±10.8%; n=3; p=0.276), but the percent of 
CD44+CXCR5+CD8+ T cells was slightly elevated in the IFN-γ KO CD8+ T cell cohort (28.7±1.2%; n=3; p=0.031) 








Figure 5: Host IFN-enhances the proliferation of CD44+CXCR5+ CD8+ T cells 
A) C57BL/6 (wild-type) and IFN-γ KO mice (both H-2b) were stimulated with mOVA (H-2b) liver lysate (2 mg 
protein) and adoptively transferred with OT-I x GFP CD8+ T cells stained with CellTrace Violet (2.5 μM). Cohorts of 
C57BL/6 and IFN-γ KO mice were treated with anti-CD4 mAb to deplete CD4+ T cells. Splenocytes were purified 
from the host mice on day 7 post-lysate treatment and analyzed by flow cytometry for reduced CellTrace Violet 
expression. In all host mice, the adoptively transferred activated CXCR5+CD8+ T cells proliferated significantly more 
than CXCR5-CD8+ T cells (C57BL/6 mice: CXCR5+=33.5±1.5% vs. CXCR5- =18.1±0.9%, p=0.001; CD4-depleted 
C57BL/6 mice: CXCR5+=30.1±1.5% vs. CXCR5-= 18.8±1.5%, p=0.017; IFN-γ KO mice: CXCR5+=19.7±1.5% 
vs.CXCR5- =18.4±1.7%, p=0.317; and CD4-depleted, IFN-γ KO mice: CXCR5+=28.2±1.5% vs. CXCR5-
=22.1±0.3%, p=0.029; n=3 for all cohorts). The proliferation of adoptively transferred, activated CXCR5+CD8+ T 
cells in C57BL/6 hosts (33.5±1.5%; n=3) was significantly elevated compared to the activated CXCR5+CD8+ T cells 
in IFN-γ KO mice (19.7±1.5%; n=3; p=0.011). B) A representative flow cytometry plot of proliferation gated on the 
number of cells that proliferated one or more times over the seven-day period was generated. The plots showed that 
CD44+CXCR5+CD8+ T cells in a wild-type mouse (40.0% CellTrace Violet low) had double the percent of cells 








Figure 6: FasL and Lamp1 expression on CD8+ TAb-supp cells is elevated by host IFN-γ 
A) C57BL/6 (wild-type), IFN-γ KO, and IFN-γR KO (all H-2b) were stimulated with FVB/N (H-2q) liver lysate and 
adoptively transferred with naïve GFP+ wild-type CD8+ T cells. Splenocytes were harvested from the hosts on day 7 
for flow cytometric analysis. FasL expression on activated, adoptively transferred CD8+ TAb-supp cells in the wild-type 
hosts (36.5±5.6%; n=3) was significantly higher than the proportion of activated CXCR5+CD8+ T cells expressing 
FasL in the IFN-γ KO hosts (6.7±5.4%; n=3; p=0.010). Additionally, the proportion of Lamp1 expression on activated 
adoptively transferred CD8+ TAb-supp cells in wild-type hosts (70.0±6.2%; n=3) was significantly higher than the same 
cell subset in IFN-γ KO hosts (6.7±5.4%; n=3; p=0.002). B) Cohorts of GFP+ C57BL/6 mice were adoptively 
transferred with naive wild-type, IFN-γ KO, or IFN-γR KO CD8+ T cells (all H-2b) and stimulated with FVB/N (H-
2q) liver lysate. Splenocytes from the host mice were purified on day 7 post-lysate treatment and stained for CD44, 
CXCR5, CD8, and various effector molecules. The proportion of FasL+ wild-type CD8+ TAb-supp adoptive transfer cells 
(50.0±35.4%; n=3) was elevated compared to the proportion of FasL+ IFN-γ KO CD8+ TAb-supp cells (8.3±6.8%; n=3; 
p=0.181). The proportion of Lamp1+ wild-type CD8+ TAb-supp cells (62.5±26.5%; n=3) showed no difference from the 







Figure 7: CD8-mediated cytotoxicity against alloantibody producing B cells is dependent on host IFN-γ and 
CD4+ T cells. C57BL/6 (wild-type), IFN-γ KO, and CD4 KO mice (all H-2b) were transplanted with FVB/N 
hepatocytes (H-2q). CD8+ T cells were isolated from the spleens of transplant mice on day 7 post-transplant. Cohorts 
of CD8+ T cells were co-cultured with B cell targets at a 1:10 ratio for four hours at 37°C / 5% CO2. The cytotoxicity 
of the CD8+ T cells against the targets was measured after the 4 hours (propidium iodide (PI) uptake). The percent 
cytotoxicity of WT CD8+ T cells against IgG1+ targets (6.5±0.7%; n=3) was significantly elevated compared to IFN-
γ KO CD8+ T cell cytotoxicity (0.5±0.1%; n=3; p<0.001) and CD4 KO CD8+ T cell cytotoxicity (0.5±0.6%; n=3; 
p<0.001). The percent cytotoxicity was unchanged against naïve wild-type B cells (WT CD8+: 1.5±0.7%, n=3; IFN-γ 




Figure 8: IFN-γ and IFN-γR are required for CD4+ T cells to enhance the quantity of CXCR5+CD8+ T cells.  
CD4 KO mice (H-2b) were adoptively transferred with CD4+ T cells from C57BL/6 (wild-type, WT), IFN-γ KO, and 
IFN-γR KO mice (all H-2b) and treated with FVB/N (H-2q) liver lysate (2mg protein). Splenocytes were isolated from 
the host mice on day 7 and analyzed by flow cytometry for CXCR5 expression on CD8+ T cells. Mice that received 
WT CD4+ T cells (5.2±1.1%; n=2) had an elevated proportion of CXCR5+CD8+ T cells compared to no adoptive 
transfer (2.9±0.5%; n=2; p=0.156). Mice that received IFN-γ KO CD4+ T cells did not show a change in CXCR5+CD8+ 
T cell quantity compared to the CD4 KO mice (3.2±0.9%; n=2; p=0.416) but were slightly reduced compared to WT 
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